Aethlon Medical Inc $AEMD

What the company doesAI summary of filing

Aethlon Medical is a clinical-stage medical device company developing the Hemopurifier, an investigational immunotherapeutic device designed to remove extracellular vesicles and enveloped viruses from blood. The company is advancing clinical development in oncology, with an ongoing safety and feasibility trial in Australia evaluating the Hemopurifier in patients with solid tumors unresponsive to anti-PD-1 monotherapy, and maintains an open investigational device exemption for life-threatening viral infections. The Hemopurifier has received FDA Breakthrough Device designation for treatment of advanced or metastatic cancer unresponsive to standard therapy and for life-threatening viruses without approved therapies. The company is pre-revenue and currently funds operations through capital raises; it spent approximately $1.9 million on research and development in fiscal year 2026 and requires FDA pre-market approval before any commercial distribution. [10-K 2026-06-10]

Segments: Hemopurifier - Oncology, Hemopurifier - Viral Infections, Hemopurifier - Organ Transplantation (pre-clinical)